New Prostate Cancer Combination Therapy Approved
The FDA-approved treatment may help adults with specific metastatic prostate cancer and HRR gene mutations.
Updated on Oct. 26, 2026 in Cancer
Live Poll
Do you trust that newly approved combination drug therapies are rigorously tested for long-term patient safety?
The FDA has approved the combination of talazoparib and enzalutamide to treat adults with metastatic castration-sensitive prostate cancer featuring HRR gene mutations. This treatment regimen is now authorized for use alongside two companion diagnostic assays to identify eligible patients.
Why it matters
This approval provides a new targeted therapy option for patients whose prostate cancer has spread and carries specific genetic mutations. By utilizing advanced gene sequencing, clinicians can better match this treatment to individuals who may see improved outcomes compared to standard care.
In the Phase 3 TALAPRO-3 trial of 599 patients, those receiving the combination therapy showed a Hazard Ratio of 0.48 for radiographic progression-free survival compared to the placebo group. The median progression-free survival for the placebo arm was 45.8 months.
The players
FDA
The federal agency responsible for protecting public health by ensuring the safety, efficacy, and security of human drugs.
The details
The treatment combines talazoparib, a PARP inhibitor, with enzalutamide to disrupt cancer cell survival. PARP inhibitors work by preventing cancer cells with HRR gene mutations from repairing their damaged DNA, ultimately causing the cells to die. Patients are identified as candidates through tumor tissue or circulating tumor DNA-based sequencing to confirm the presence of HRR mutations.
Timeline
October 26, 2026: FDA approved talazoparib and enzalutamide combination therapy.
Health Landscape
This approval advances the use of precision medicine in prostate cancer, shifting away from one-size-fits-all treatments toward therapies targeted at specific genetic profiles. It builds upon the established clinical trajectory of the TALAPRO-3 trial within the oncology landscape.
Patients with metastatic prostate cancer should consult with their oncology team to determine if tumor or DNA sequencing for HRR gene mutations is appropriate. It is also important to discuss potential side effects, including myelosuppression and the risks of secondary malignancies, with your doctor.
The takeaway
This new therapy offers a targeted approach for metastatic prostate cancer by matching treatment to specific genetic markers. Ask your healthcare provider about whether genomic testing or recent treatment approvals are relevant to your specific diagnosis and stage of care.
Further reading
For more information on how doctors approach treatment decisions for advanced disease, visit Cancer.
More information
Review the official FDA drug approval and information page for full prescribing details.
Live Poll
Do you trust that newly approved combination drug therapies are rigorously tested for long-term patient safety?
